Teva Pharmaceutical Industries Ltd - Asset Resilience Ratio
Teva Pharmaceutical Industries Ltd (TEVA) has an Asset Resilience Ratio of 0.00% as of December 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1994–2018)
This chart shows how Teva Pharmaceutical Industries Ltd's Asset Resilience Ratio has changed over time. Check TEVA PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Teva Pharmaceutical Industries Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see TEVA market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA2.00 Million | 0.0% |
| Total Liquid Assets | ILA2.00 Million | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Teva Pharmaceutical Industries Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Teva Pharmaceutical Industries Ltd Industry Peers by Asset Resilience Ratio
Compare Teva Pharmaceutical Industries Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Suven Pharmaceuticals Limited
NSE:SUVENPHAR |
Drug Manufacturers - Specialty & Generic | 6.76% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
Bausch Health Companies Inc
TO:BHC |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Shandong Lukang Pharmaceutical Co Ltd
SHG:600789 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Teva Pharmaceutical Industries Ltd (1994–2018)
The table below shows the annual Asset Resilience Ratio data for Teva Pharmaceutical Industries Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.00% | ILA2.00 Million ≈ $5.36K |
ILA60.68 Billion ≈ $162.69 Million |
-0.02pp |
| 2017-12-31 | 0.02% | ILA14.00 Million ≈ $37.53K |
ILA70.61 Billion ≈ $189.32 Million |
-0.71pp |
| 2016-12-31 | 0.73% | ILA679.00 Million ≈ $1.82 Million |
ILA92.89 Billion ≈ $249.03 Million |
+0.71pp |
| 2015-12-31 | 0.02% | ILA11.00 Million ≈ $29.49K |
ILA54.26 Billion ≈ $145.46 Million |
-0.14pp |
| 2014-12-31 | 0.16% | ILA73.00 Million ≈ $195.71K |
ILA46.42 Billion ≈ $124.45 Million |
+0.15pp |
| 2013-12-31 | 0.00% | ILA2.00 Million ≈ $5.36K |
ILA47.51 Billion ≈ $127.37 Million |
-0.09pp |
| 2010-12-31 | 0.09% | ILA36.00 Million ≈ $96.51K |
ILA39.05 Billion ≈ $104.70 Million |
-0.66pp |
| 2009-12-31 | 0.75% | ILA253.00 Million ≈ $678.28K |
ILA33.81 Billion ≈ $90.64 Million |
+0.59pp |
| 2008-12-31 | 0.16% | ILA53.00 Million ≈ $142.09K |
ILA32.90 Billion ≈ $88.21 Million |
-5.76pp |
| 2007-12-31 | 5.92% | ILA1.39 Billion ≈ $3.72 Million |
ILA23.41 Billion ≈ $62.77 Million |
+2.45pp |
| 2006-12-31 | 3.48% | ILA712.00 Million ≈ $1.91 Million |
ILA20.47 Billion ≈ $54.88 Million |
-5.53pp |
| 2005-12-31 | 9.01% | ILA935.50 Million ≈ $2.51 Million |
ILA10.39 Billion ≈ $27.85 Million |
+6.34pp |
| 2004-12-31 | 2.67% | ILA256.80 Million ≈ $688.47K |
ILA9.63 Billion ≈ $25.82 Million |
-2.78pp |
| 2003-12-31 | 5.44% | ILA322.10 Million ≈ $863.54K |
ILA5.92 Billion ≈ $15.86 Million |
+0.35pp |
| 2002-12-31 | 5.09% | ILA235.70 Million ≈ $631.90K |
ILA4.63 Billion ≈ $12.40 Million |
+4.48pp |
| 2001-12-31 | 0.61% | ILA21.23 Million ≈ $56.91K |
ILA3.46 Billion ≈ $9.28 Million |
+0.48pp |
| 2000-12-31 | 0.14% | ILA3.90 Million ≈ $10.46K |
ILA2.86 Billion ≈ $7.66 Million |
-0.87pp |
| 1999-12-31 | 1.01% | ILA17.23 Million ≈ $46.18K |
ILA1.71 Billion ≈ $4.60 Million |
+0.86pp |
| 1998-12-31 | 0.15% | ILA2.10 Million ≈ $5.63K |
ILA1.44 Billion ≈ $3.85 Million |
-0.50pp |
| 1997-12-31 | 0.65% | ILA7.70 Million ≈ $20.64K |
ILA1.19 Billion ≈ $3.19 Million |
+0.00pp |
| 1996-12-31 | 0.64% | ILA8.00 Million ≈ $21.45K |
ILA1.24 Billion ≈ $3.33 Million |
-0.54pp |
| 1995-12-31 | 1.18% | ILA10.30 Million ≈ $27.61K |
ILA871.30 Million ≈ $2.34 Million |
-0.05pp |
| 1994-12-31 | 1.23% | ILA8.30 Million ≈ $22.25K |
ILA676.00 Million ≈ $1.81 Million |
-- |
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more